Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Merck
Mallinckrodt
Medtronic
QuintilesIMS
Cerilliant
Daiichi Sankyo
Healthtrust
Fuji

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021398

« Back to Dashboard

NDA 021398 describes COMBIGAN, which is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the COMBIGAN profile page.

The generic ingredient in COMBIGAN is brimonidine tartrate; timolol maleate. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the brimonidine tartrate; timolol maleate profile page.
Summary for 021398
Tradename:COMBIGAN
Applicant:Allergan
Ingredient:brimonidine tartrate; timolol maleate
Patents:11
Formulation / Manufacturing:see details
Pharmacology for NDA: 021398
Suppliers and Packaging for NDA: 021398
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
COMBIGAN brimonidine tartrate; timolol maleate SOLUTION/DROPS;OPHTHALMIC 021398 NDA Allergan, Inc. 0023-9211 N 0023-9211-15
COMBIGAN brimonidine tartrate; timolol maleate SOLUTION/DROPS;OPHTHALMIC 021398 NDA Allergan, Inc. 0023-9211 N 0023-9211-05

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrength0.2%;EQ 0.5% BASE
Approval Date:Oct 30, 2007TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Apr 19, 2022Product Flag?Substance Flag?Delist Request?
Patented Use:REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
Patent:➤ Try a Free TrialPatent Expiration:Apr 19, 2022Product Flag?Substance Flag?Delist Request?
Patented Use:REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
Patent:➤ Try a Free TrialPatent Expiration:Jan 19, 2023Product Flag?YSubstance Flag?Delist Request?Y

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
McKesson
Medtronic
Colorcon
US Department of Justice
Cipla
Teva
AstraZeneca
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.